UCB Pharma Overview
- Founded
-
1946

- Status
-
Acquired/Merged
- Employees
-
8,506

- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
1
UCB Pharma General Information
Description
Developer and marketer of drugs. The company specializes in the research, development and market of drugs, pharmaceutical and biotechnological products.
Contact Information
Website
ucb.de
Formerly Known As
Schwarz Pharma AG
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Office
- Alfred-Nobel-Strasse 10
- 40789 Monheim
- Germany
+49 02173 000000
UCB Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
UCB Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details

Developer and marketer of drugs. The company specializes in the research, development and market of drugs, pharmaceutica
Pharmaceuticals
Monheim, Germany
8,506
As of 2011
0.000
0000-00-00
000000&0
UCB Pharma Competitors (44)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Landsteiner Scientific | Private Equity-Backed | Mexico City, Mexico | 0000 | 000.00 | 0000000 0000 | |
00000000 000000 | Corporation | Tokyo, Japan | 00000 | 00000000 | ||
0000000 0000000000 | Corporation | Yilan City, Taiwan | 00 | |||
00000 | Corporation | Basel, Switzerland | 000000 | 00.000 | 00000000000 | 00.000 |
00000000 | Formerly VC-backed | Dublin, Ireland | 0000 | 00.000 | 000000000 | 00.000 |
UCB Pharma Patents
UCB Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220298112-A1 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | Pending | 17-Jun-2019 | 0000000000 | |
CA-3137091-A1 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | Pending | 17-Jun-2019 | 0000000000 | |
EP-3983384-A1 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | Pending | 17-Jun-2019 | 0000000000 | |
EP-3810587-A1 | Substituted alkoxypyridinyl indolsulfonamides | Active | 20-Jun-2018 | 0000000000 | |
EP-3810587-B1 | Substituted alkoxypyridinyl indolsulfonamides | Active | 20-Jun-2018 | C07D401/12 |
UCB Pharma Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Eric Schemann | Geschäftsführung | ||
Peter Mitterhofer | Geschäftsführung | ||
Mark Mcdade | Chief Operating Officer |
UCB Pharma Signals
UCB Pharma Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 000000 | 22-Nov-2011 | 0000000000 | Drug Discovery |